Stock market announcement archive

LIFE: CSO – Switch from consultancy agreement to employee

December 15, 2023
Bergen, Norway, December 15th, 2023, Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), informs that the formal relationship with the Company’s Chief Scientific Officer (CSO) will be adjusted from an consultancy agreement to an employment agreement. Since 2013, Prof. Dr. Dr. Med. Andreas Pfützner has […]
Read more

LIFE: Notofication of trade by party closely related to primary insider

December 15, 2023
Bergen, Norway, December 15th, 2023. Islay Ventures GmbH (“IV”) a company wholly owned and controlled by Lifecare CSO Prof. Dr. Dr. Med Andreas Pfützner, has today reported to have sold 320,800 shares in the Company at an average price of NOK 3.476. The transaction represents 12,24% of IV’s original holding. After the transaction IV owns […]
Read more

LIFE: Final purchase order for automated production components – micro-fluidic handling and dispensing devices

December 13, 2023
Bergen, Norway, December 13th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that yet an additional preparational step for the Company’s automated production has been met as Lifecare has placed the purchase order for a BioScaffolder (“BS 3.3) and a customized Nano-Plotter […]
Read more

LIFE: Purchase order on scanning electron microscope from Zeiss

November 28, 2023
Bergen, Norway, November 28th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare has placed the purchase order for a SEM (abbreviation for Scanning Electron Microscope) from the German supplier Carl Zeiss AG. Reference is made to Lifecare’s list of trigger […]
Read more

LIFE: Successful ISO 13485 audit

November 20, 2023
Bergen, Norway, November 20th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), can disclose that Lifecare Laboratory (Mainz, Germany) has been successfully audited as part of the upcoming ISO 13485 certification. Reference is made to Lifecare’s list of trigger events, as presented at the […]
Read more

Lifecare Q3 2023 report and webcast

November 13, 2023
Lifecare AS will present Q3 2023 financial and operational status in a webcast Tuesday 14 November. The webcast will be for all shareholders and interested parties at 10:30 – 11:15 CET. Lifecare's CEO Joacim Holter presents the company's Q3 report followed by a Q&A session where Joacim Holter will answer questions submitted in advance. Questions […]
Read more

LIFE: The European Patent Office intends to issue new Lifecare patent

November 8, 2023
Bergen, Norway, November 8th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that the European Patent Office (EPO) has reported its intent to grant Lifecare a new patent. Lifecare will review the examining division’s comments to the patent application and respond to the […]
Read more

LIFE: Lifecare receives regulatory approval to start LFC-SEN-002

November 7, 2023
Bergen, Norway, November 7th, 2023: Today, Lifecare AS (LIFE), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), announces that The Norwegian Food Safety Authority (NFSA) has awarded all necessary approvals to start LFC-SEN-002. Reference is made to Lifecare’s list of trigger events, as presented at the semi-annual report of […]
Read more

Mandatory notification of trade

November 3, 2023
Bergen, Norway 3 November 2023: Reference is made to stock exchange notification 1 June 2022 with notification of trade of 25 000 shares by primary insider Joacim Holter. Enclosed to the stock exchange notification was a KRT 1500 form informing that the shares was planned to be transferred to Joacim Holters children. Today, Lifecare has […]
Read more

Lifecare – Valuation Report of the Sencell technology (CGM) for diabetes

November 1, 2023
Bergen, Norway, November 1st, 2023: Today, Lifecare AS (LIFE) (the “Company”), a clinical stage medical sensor company developing the next generation Continuous Glucose Monitor (CGM), publishes a new valuation report of Lifecare’s CGM-technology. The report is enclosed and available on the bottom of this text. Commissioned by Lifecare, the life science technology valuation-company Xplico has […]
Read more